Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice
Open Access
- 1 April 2005
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 313 (1) , 395-402
- https://doi.org/10.1124/jpet.104.076406
Abstract
The metabotropic glutamate receptor subtype mGlu5 modulates central reward pathways. Many transmitter systems within reward pathways affect feeding. We examined the potential role of mGlu5 in body weight regulation using genetic and pharmacological approaches. Adult mice lacking mGlu5, mGluR5-/-, weighed significantly less than littermate controls (mGluR5+/+), despite no difference in ad libitum food intake. After overnight food deprivation, mGluR5-/- mice ate significantly less than their mGluR5+/+ controls when refeeding. When on a high fat diet, mGluR5-/- mice weighed less and had decreased plasma insulin and leptin concentrations. The selective mGlu5 antagonist MTEP [3-[(2-methyl-1,3-thiazol-4-yl)-ethynyl]-pyridine; 15 mg/kg s.c.] reduced refeeding after overnight food deprivation in mGluR5+/+, but not mGluR5-/- mice, demonstrating that feeding suppression is mediated via a mGlu5 mechanism. MTEP (1–10 mg/kg) decreased night-time food intake in rats in a dose-related manner. At 10 mg/kg, MTEP injected at 8.5, 4.5, or 0.5 h before refeeding reduced overnight food intake by approximately ∼30%. Diet-induced obese (DIO) and age-matched lean rats were treated for 12 days with MTEP (3 or 10 mg/kg/day s.c.), dexfenfluramine (3 mg/kg/day s.c.), or vehicle. Daily and cumulative food intakes were reduced in DIO rats by MTEP and dexfenfluramine. Weight gain was prevented with MTEP (3 mg/kg), and weight and adiposity loss was seen with MTEP (10 mg/kg) and dexfenfluramine. Caloric efficiency was decreased, suggesting increased energy expenditure. In lean rats, similar, although smaller, effects were observed. In conclusion, using genetic and pharmacological approaches, we have shown that mGlu5 modulates food intake and energy balance in rodents.Keywords
This publication has 39 references indexed in Scilit:
- The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of AnxietyNeuropsychopharmacology, 2004
- mGluR5 Antagonist MPEP Reduces Ethanol-Seeking and Relapse BehaviorNeuropsychopharmacology, 2003
- In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)European Journal of Pharmacology, 2003
- Increased Dietary Fat Attenuates the Anorexic Effects of Intracerebroventricular Injections of MTIIEndocrinology, 2003
- Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic–pituitary–adrenal axis activity: interaction with serotonergic systemsNeuropharmacology, 2003
- SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in ratsBehavioural Pharmacology, 2002
- [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo CharacterizationThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant miceNature Neuroscience, 2001
- Effects of Obesity on PharmacokineticsClinical Pharmacokinetics, 2000
- Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptorsPsychopharmacology, 1997